Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muromonab-CD3 + cyclophosphamide
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Muromonab-CD3 + cyclophosphamide is a combination therapy investigated for the treatment of metastatic cancer and locally progressive primary brain tumors. Muromonab-CD3 (OKT3) is a murine monoclonal antibody that targets the CD3 epsilon chain of the T-cell receptor complex, leading to T-cell depletion and immunosuppression. In this clinical trial context, it was combined with low-dose cyclophosphamide, an alkylating agent that, at low doses, is thought to enhance anti-tumor immune responses by selectively depleting regulatory T cells (Tregs). The study was sponsored by St. Vincent Medical Center - Los Angeles to evaluate the safety and efficacy of this immunomodulatory approach in advanced malignancies.
- Brand names
- Orthoclone OKT3
- Other names
- muromonab-CD3muromonab-CD-3muromonab-CD 3cyclophosphamideantibody therapy
02
Targets
CD3 (T-cell surface glycoprotein CD3)DNA
Beyond the preview
Go deeper on muromonab-CD3 + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muromonab-CD3 + cyclophosphamide.